Here's What to Expect From Cardinal Health's Next Earnings Report
Here's What to Expect From Cardinal Health's Next Earnings Report.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Cardinal Health, Inc. (CAH), headquartered in Dublin, Ohio, operates as a healthcare services and products company. Valued at $53.2 billion by market cap, the company's services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising. The healthcare giant is expected to announce its fiscal fourth-quarter earnings for 2026 before the market opens on Tuesday, Aug. 11.
Ahead of the event, analysts expect CAH to report a profit of $2.42 per share on a diluted basis, up 16.4% from $2.08 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports.
Walmart Stock's Extended Downturn Could Trigger a Possible Comeback
The Biggest Risk to SpaceX Stock Comes After Earnings. Here Are The Numbers You Should Keep An Eye On.
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
For the full year, analysts expect CAH to report EPS of $10.77, up 30.7% from $8.24 in fiscal 2025. Its EPS is expected to rise 11.5% year over year to $12.01 in fiscal 2027.
CAH stock has outperformed the S&P 500 Index's ($SPX) 18.9% gains over the past 52 weeks, with shares up 40.4% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF's (XLV) 19.4% returns over the same time frame.
CAH outperformed as investors gained confidence in continued momentum across specialty, biosimilars, and growth businesses. A top-line miss in Pharma and Specialty Solutions reflected moderating GLP-1 growth and IRA pricing pressures, but this was offset by 20%+ specialty revenue growth, progress on Solaris and ADS integrations, and operational resilience. Management raised full-year profit guidance, citing cost efficiencies, automation investments, and synergy realization, while noting that tariff and IRA uncertainties remain.
Analysts' consensus opinion on CAH stock is bullish, with a "Strong Buy" rating overall. Out of 17 analysts covering the stock, 14 advise a "Strong Buy" rating, and three give a "Hold." CAH's average analyst price target is $252.56, indicating a potential upside of 14.5% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Sinergia Empresarial continuará el seguimiento de esta información sobre here's What to Expect From Cardinal Health's Next Earnings Report y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
